Has Se­lec­ta found a way around gene ther­a­py's de­liv­ery prob­lem? Take­da puts down $1B-plus to find out

While gene ther­a­pies were tra­di­tion­al­ly thought of as one-and-done treat­ments, sci­en­tists now see a ben­e­fit in re­dos­ing pa­tients down the road. The on­ly prob­lem? Some …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER